Research group focused on circulating biomarkers and clinical utility-oriented translational research
Italy
Joined January 2019
- Tweets99
- Following54
- Followers291
- Likes72
The Liquid Biopsy Research Group retweeted
Can #fragmentomics become a new monitoring #biomarker in metastatic breast cancer? 🔬
👉 Here we explore a mutation-agnostic, cost-effective approach tested in the MAGNETIC.1 trial—a longitudinal study of first-line HR+/HER2- MBC.
doi.org/10.1016/j.tranon.202…
The Liquid Biopsy Research Group retweeted
🏁 Our program on cellular residual disease in triple negative breast cancer is about to launch!
Detecting circulating tumor cells in early #TNBC will provide deeper insights into the metastatic process and #immunotherapy response
#BreastCancer #LiquidBiopsy #CTC @CroAviano
🔬 Exciting Liquid Biopsy session under the patronage of the International Society of Liquid Biopsy
📍 View the full program and register here: focusontop.it
#FocusOnTop #LiquidBiopsy #CTCs #ctDNA #PrecisionOncology #FTOP25 #BreastCancer @isliquidbiopsy
🗓️Mark Your Calendars!
Join us at FOCUS on TOP in Udine, Italy, on March 17-18, 2025!
📍 Venue: Hotel Là di Moret, Udine, Italy
🚆 Train: Udine railway station
✈️ Airports: Venice Marco Polo, Trieste - Friuli Venezia Giulia
🌐 More Info: focusontop.it
🎤 Hear it from our speakers!
On March 17, 2025, at 14:00, @ReduzziCarol will take the stage at FOCUS on TOP in the #LiquidBiopsy Session, exploring the role of circulating tumor cells (#CTCs) in #MRD monitoring with #ctDNA.
Program and registration: 👇
ecm.meetingsrl.eu/focus_TOP2…
The Liquid Biopsy Research Group retweeted
CDK4/6 inhibitors: mechanisms of resistance and where to find them.
An outside of the box review
Main takeaways:
🛑RB1 loss in #ctDNA predicts poorer PFS
⚠️CCNE1 gain impacts PALOMA-3 outcomes
🧩Role of ESR1 still unclear
Read more👇
sciencedirect.com/science/ar…
#bcsm #BreastCancer
With the growing efficacy of new antiHER2 agents, biomarker-driven de-escalation will become increasingly crucial for #PrecisionMedicine in #BreastCancer
#bcsm
@lindacucciniel1 @BlondeauxEva
Ancillary analysis of the GIM14 study
shows features linked to radiologic complete response (rCR) in HER2+ #MBC:
🌡️ HER2 IHC 3+
🩻 Non-visceral involvement
🎯 1 metastatic site
Setting the stage for the GIM36/INSPIRE1 #liquidbiopsy #MRD trial #bcsm
nature.com/articles/s41523-0…
Intriguing data presented by @lfoffano97 at the #SABCS24 poster session on how #ctDNA can be leveraged to enhance disease monitoring in metastatic #BreastCancer.
Paving the way to a new #liquidbiopsy informed RECIST
@CtcLaboratory #PrecisionMedicine #bcsm
Our @LGerratana shows the perspectives of adjuvant treatment de-escalation at the #AIOM24 #breastcancer educational session. #liquidbiopsy will play a crucial role in transitioning from prognostication to actual monitoring. #ctDNA #PrecisionMedicine @uniud @CroAviano
The Liquid Biopsy Research Group retweeted
🔬 #ASCO2024 Insight: Dr @LGerratana discusses the genomic profiling of PR-negative and ER-low breast cancer subtypes. ER-low tumours show a mutational profile similar to triple-negative breast cancer, suggesting benefits from immunotherapy.
The Liquid Biopsy Research Group retweeted
#ctDNA is gaining importance in #breastcancer. But what are its real clinical prospects? Excited to share our perspective: 'Is ctDNA ready to outpace imaging in monitoring early and advanced breast cancer?' 👉 doi.org/10.1080/14737140.202…
The Liquid Biopsy Research Group retweeted
Is ER low metastatic #BreastCancer a TNBC-like disease subtype?
Check our circulating tumor DNA analysis
📍Poster Bd # 17 - Hall A, Metastatic Breast Cancer session
⏱️ 9:00 AM - 12:00 PM #ASCO24 #ctDNA #bcsm #liquidbiopsy
The Liquid Biopsy Research Group retweeted
Say hello to OLGA, @CroAviano persOnaLized oncoloGy cAre flow platform
It’s time to move from the paradigm of #PrecisionMedicine in #Oncology to a broader concept of #Personalized #Care, where treatments and monitoring strategies are holistically tailored around every person.
The Liquid Biopsy Research Group retweeted
Great opportunity to get in touch with the International Society of Liquid Biopsy (ISLB @isliquidbiopsy) at booth 10027! #ASCO24 #LiquidBiopsy
🚀 Excited to be at #ASCO2024! Visit us at booth 10027 to learn more about the International Society of Liquid Biopsy (ISLB) and our latest advancements. See you there! #LiquidBiopsy #CancerResearch #ISLB #ASCO2024
The Liquid Biopsy Research Group retweeted
Join Francois-Clement Bidard at the 20th Anniversary of Circulating Tumor Cells in Granada, Spain from May 24-25, 2024.
Francois-Clement Bidard, MD PhD, is a Professor of Medical Oncology at Institut Curie & Versailles University, and also the vice-chair or the French breast cancer research group UCBG/Unicancer.
For more information, please contact [email protected].
#CTC20thAnniversary #SpeakerSpotlight
@MJOSESERRANO19
@MCristofanill
The Liquid Biopsy Research Group retweeted
Be part of the 20th Anniversary of Circulating Tumor Cells, organized by ISLB!
📅 Save the date for May 24 - 25, 2024, and join us as we unveil the impact of Circulating Tumor Cells, exploring two decades of discovery and clinical advancements in solid tumors.
Chairs:
@MCristofanill
@MJOSESERRANO19
Hosted at Centro Pfizer-University of Granada-Junta De Andalucia De Genomica E Investigación Oncologica, Granada, Spain.
Don't miss this opportunity to be part of the future of cancer research and treatment! More information please write to [email protected]
The Liquid Biopsy Research Group retweeted
What is the role of synonymous mutations (SYN) and variants of unknown significance (VUS) detected though #ctDNA next generation sequencing?
Some interesting insights presented by @Elisabetta_mol at the #SABCS23 poster session
#LiquidBiopsy #MBC – at San Antonio, TX
The Liquid Biopsy Research Group retweeted
Check our companion posters on genetic and epigenetic #ctDNA profiling according to PR status in metastatic #breastcancer.
🔴during 1st line ET
🔼 ESR1 promoter methylation in PRpos
🔴after 1st line:
🔼ESR1 mut in PRpos #MBC
🔼GATA3 mut in PRneg #MBC
#SABCS23 #liquidbiopsy – at San Antonio, TX
The Liquid Biopsy Research Group retweeted
Moving from prognostication to pattern of progression at the #ESMO23 poster session with @lindacucciniel1 . Hazard distribution has different patterns across clinical and #LiquidBiopsy subgroups: can we #personalize disease monitoring in metastatic #BreastCancer?
The Liquid Biopsy Research Group retweeted
A recent prospective study delved into baseline pharmacological profiling in patients treated for metastatic #BreastCancer using #palbociclib
🧵3/5
linkinghub.elsevier.com/retr…
#MBC